ABL Bio Corp.
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
Latest on ABL Bio Corp.
The second quarter was a mixed bag of encouraging and disappointing news for the South Korean biopharma sector, ranging from cancellation of out-licensing deals and discontinuation of clinical trials
In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu
The last few years have been bittersweet for ABL Bio. After reaching a major deal with Sanofi in 2021, the South Korean biotech was excited because it was also discussing a potential tie-up with GSK
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s